To detect parameters that may augment the therapeutic strategy in patients with a cerebral arteriovenous malformation (AVM) that is considered equally suitable for treatment by neurosurgery or radiosurgery, we compared the efficacy and risks of these two methods in a paired series with similar patient and AVM characteristics. PATIENTS AND METHODS: Two series of patients with AVM were studied, including a series of 39 patients treated using microsurgery (MS) and another series of 39 patients treated via radiosurgery (RS). These series were paired for age and sex, initial symptoms, size, location and Spetzler-Martin grade, and presence of embolization preceding treatment. We compared the posttreatment outcome in the two groups with respect to obliteration rate, neurological status, mortality rate, and recurrent bleeding. Statistical analysis was performed using paired Student's t test. RESULTS: The Glasgow Outcome Scale values and Modified Rankin Scores measured at discharge and 12 to 24 months were significantly better in the RS series than in the MS series. The obliteration rate tended to be higher in the MS series (91% versus 81%; P ϭ 0.10, not significant), whereas the rate of neurological deficit was higher in the MS series than in the RS series(P Ͻ 0.001). The mortality rate was not significantly different in the two series, but the rate of recurrent bleeding was higher in the RS group (10% versus 0%; P ϭ 0.04). CONCLUSIONS: Although the rate of cure was similar for patients treated with MS and RS, neurological morbidity was higher after MS and recurrent bleeding was more frequent after RS.
I
n every series of arteriovenous malformation (AVM) treatments performed via surgery or radiosurgery, it is possible to identify AVMs that were equally suitable (according to their characteristics) for treatment by either microsurgery (MS) or radiosurgery (RS). The purpose of this study was to evaluate the results of these two methods by comparing similar AVM patient populations. A careful search of the population of patients with AVM treated by our group revealed pairs of patients who presented with shared pretreatment characteristics, but were treated differently and had different outcomes.
Although a randomized prospective study may identify which treatment is the best choice given specific circumstances, such a task is not feasible, mainly for ethical reasons. Our idea, therefore, was to compare the outcomes of patients who were similar to one another before treatment (who had similar patient and AVM characteristics) and use the comparison as a surrogate for randomization between the two types of treatments. Despite the retrospective character of the study, the results would allow us to provide answers to questions typically asked by patients regarding the potential outcome differences between MS and RS treatments in this category of operable AVMs, and our answers would better reflect reality and hold more meaning than the results of larger published series. From a physician's point of view, such a comparison would make it easier to explain the benefits and disadvantages of two different treatments that are appropriate for the same kinds of lesions. Additionally, it seemed to us that gaining knowledge about treatment outcomes in such circumstances might provide other benefits in addition to improving the quality of the patient's informed consent.
PATIENTS AND METHODS

Patients
Between January of 1984 and December of 1998, 150 patients underwent microsurgery for cerebral AVM in the Neurosurgical Department of Lariboisière Hospital in Paris. During the same period, 705 patients received irradiation for AVM via linear accelerator radiosurgery (RS) from the Sainte Anne-Tenon group. These three institutions have cooperated in AVM treatment since 1984. Accordingly, in each database it was possible to locate records of several patients who were equally suitable candidates for either MS or RS, and who had common clinical patient and AVM characteristics. We assembled the "matching" patients in pairs, and within each pair, one individual was treated with MS, and the other was treated with RS. Our task was then to study and compare the posttreatment outcomes between the individual patients in each pair.
We began our search in the surgical database and assembled a list of patients who had complete records with regard to clinical findings before and after MS or RS treatment, follow-up events, and imaging data. In the RS database, where more cases were available, it was possible to identify cases with matching characteristics. Thus, we were able to assemble paired cases with similar pretreatment parameters that differed only in treatment and outcome. Finally, 39 pairs were formed, and these patients constituted our study population.
We organized our 39 pairs of patients into two "parallel series" of 39 patients each. One series was composed of 39 patients who were treated with MS, and symmetrically, the other series included 39 otherwise-identical RS patients. For each pair of patients, we analyzed long-term outcomes and compared them to published MS and RS treatment data. Although our series involves a relatively small number of patients (n ϭ 78), the study has merit in its specificity. A targeted focus on the differences between these two treatment options could provide additional clarity (for both patients and surgeons) when treatment decisions are being made.
Shared Characteristics
The shared pretreatment characteristics that we considered and collected for the study included patient age and sex, presenting symptoms, nidus size, topography, Spetzler-Martin grade, and existence of previous embolization (see Tables 1, 2 , and 3 for details). Patients were strictly paired for age, for presenting symptom when that symptom was hemorrhage, and for anatomic topography. Patients were paired as closely as possible for presenting symptoms other than existence of hemorrhage, sex, nidus size, Spetzler-Martin grade, and previous embolization.
Some of the initial or posttreatment data were not available at the time of writing. The corresponding incomplete cases were not included in this study, which reduces the potential number of paired cases to 39 patients. Ages were similar, and the male:female sex ratios were slightly-but not statistically-different (0.95 for MS and 1.17 in RS).
The types and modalities of treatment, including any prior embolization, follow-up clinical information, and imaging data, were recorded. For patients who received RS treatment, this consisted of the usual periodic follow up of an annual clinical examination, magnetic resonance imaging (MRI), and angiography. Only angiographic obliteration was taken into account. Surgically treated patients underwent followup angiography and periodic clinical examinations with associated MRI as necessary.
Patients in the pairs treated with MS experienced more minor symptoms (for example, 25% of MS patients had headaches versus 17% of RS patients). However, bleeding rates were identical (6.2%), and there were progressive neurological deficits (10. 2%) in MS patients, whereas RS patients had none. The seizure rates were 31% for RS and 23% for MS patients, values that were probably related to recruitment bias.
The nidus pretreatment (but postembolization) mean diameter was a little larger (but not statistically different) in MS (31.4 mm) than in RS (25.2 mm) patients. This seemed partially related to the generally accepted principle that nidus candidates for RS should present a mean diameter close to 25 mm. There were fewer nidus-size limitations for MS patients. (Nidus topography within the of paired series is shown in Table 2 .) Correspondingly, the greater number of prior embolizations in RS (46%) than in MS (36%) patients could be interpreted as reflecting the size limitation principle. However, each patient in these two groups was a candidate for either of the two treatments.
The two series had exactly the same topographic distributions. Except for temporal location, which was higher in the present series, all anatomic sites were represented in equal proportions when compared with the entire series of 705 patients treated with RS.
Spetzler-Martin Grading
We used Spetzler-Martin grading (53) to select study candidates and to evaluate our results (see Table 3 ). Spetzler-Martin grades of patients in our paired series were compared with those of the 705 patients who received linear accelerator RS.
Analysis of the pretreatment data showed that principal pretreatment characteristics of the patients and their AVMs were homogenous, which indicates that the selection methodology used was sound. The difference between the two series was reduced to the type of treatment chosen, and thus, the ensuing consequences with respect to long-term outcome.
Treatment Methods Embolization
In the classical AVM treatment approach, embolization can be considered as a first step of treatment, as it reduces nidus size, volume, or flow via occlusion of one or more arteriovenous shunts. 
Microsurgery
The goal of MS is complete AVM excision. The decision to pursue MS should be based on the surgeon's abilities, the patient's characteristics, and appreciation of the operative risk, which is gauged primarily using Spetzler-Martin grading. We correlated Spetzler-Martin grade with operative mortality and morbidity for a given AVM. This grading also allowed us to compare AVM series.
Radiosurgery
The details of irradiation have already been described (48) . In Summary, the 39 RS patients had a stereotactic pendular irradiation with 15 MeV circular x-ray beams from a LINAC Saturne 43 (Compagnie Generale de Radiologie-General Electric, France) in accordance with the Betti technique, whereby arc therapy is applied to the patient within a Talairach frame and in a sitting position.
The median dose on peripheral isodose was 25 Gy (mean, 24 Gy). One isocenter was used in 77% of patients (30 out of 39 patients).
Follow Up
For the whole series, mean and median follow-up times were, respectively, 23 and 12 months (minimum, 11 mo; maximum, 168 mo). For MS patients, mean and median follow-up times were, respectively, 12.3 and 12 months (minimum, 12 mo; maximum, 25 mo). For RS patients, mean and median follow-up times were, respectively, 33.6 and 25 months (minimum, 11 mo; maximum, 168 mo). For most patients in the RS series, follow-up examinations were discontinued after AVM obliteration.
Outcome Data
Outcome data are shown in Table 4 . Initial pretreatment status was evaluated using the Glasgow Coma Scale (GCS), which is a scale used to evaluate the patient's level of consciousness and degree of axial suffering. This scale was initially created by Teasdale and Jennett (54) for craniocerebral trauma, and is based on eye-opening, motor, and verbal responses with or without stimulation.
The clinical posttreatment manifestations were graded according to the Glasgow Outcome Scale (GOS) (21) . Posttreatment status was evaluated after 48 hours using the GCS and then at discharge using the GOS and modified Rankin score (MRS). The last GOS and MRS evaluations were performed at 12 to 24 months after treatment.
Obliteration Rate and Delay
Obliteration rate was assessed via angiography for MS and RS patients. Delay of obliteration was defined as the amount of time that elapsed between the radiosurgery and the first angiography that showed obliteration.
Complications
Complications (mortality and morbidity) involved recurrent bleeding and posttreatment neurological deficits, including neurological deficits related to treatment. There was not enough available MRI to study and compare the parenchymal changes.
Statistical Analysis
Statistical analysis was performed using paired Student's t test. It was used for paired-samples analysis with two groups to determine whether the average difference of each pair was zero. The maximum significance level was 0.05.
The actuarial risk of hemorrhage after RS was obtained by computing the ratio of the number of patients that presented with one or more episodes of bleeding after RS to the number of patient-years at risk (the number of patients times the number of years from RS to AVM obliteration). These patients at risk included all patients with nonobliterated AVM. Tables 4 and 5 . As previously mentioned, the selection methodology of pairing in series patients treated using MS and RS confirms the homogeneity of main pretreatment characteristics. Now we consider the differences between the two series, which were the treatment types and the corresponding consequences on long-term patient outcome. Initially, the neurological deficit rates were 31% for the MS versus 41% for the RS series, which were not significantly different.
RESULTS
Results are presented in
Other Perioperative Parameters
In the RS series, the pre-and posttreatment early status (at 48 h after treatment and at discharge) indicator values showed better and highly significant neurological results:
• initial GCS of 15 for RS versus 13.64 for MS patients (P ϭ 0.0049), • initial posttreatment GCS of 15 for RS versus 13.58 for MS patients (P ϭ 0.0049), • GCS at 48 hours was 15 for RS versus 12.89 for MS patients (P ϭ 0.0021), • GOS at discharge was 4.89 for RS versus 4.2 for MS patients (P ϭ 0.00028), • GOS at 12 to 24 months was 4.89 for RS versus 4.39 for MS patients (P ϭ 0.002), • MRS at discharge was 1.10 for RS versus 2.07 for MS patients (P ϭ 0.0006),and • MRS at 12 to 24 months was 0.95 for RS versus 1.41 for MS patients (P ϭ 0.05).
Mortality. There was one postoperative death in the MS series and none in the RS series (see Table 5 ). The patient's cause of death was postoperative worsening (GCS was 14 preoperatively and 4 postoperatively) with hydrocephalus and death occurring 3 months after surgery.
Risk of Hemorrhage. The primary problem associated with RS, aside from the delay before (and secondary to) obliteration, is the recurrence of bleeding. In the RS series, there were three patients, and in the MS series, there were none (P ϭ 0.04). The actuarial risk of hemorrhage after RS was 2.70% per year. There was no death or new deficit associated with these late bleedings.
Morbidity. The posttreatment morbidity period showed a similar trend (see Table 5 ); in MS patients, the rate of neurological deficit was significantly higher (39%) than in RS patients (5%; P ϭ 0.0008).
In the MS series, there was one postoperative death, and there were none in the RS series. In the long-term outcome results, the differences between the treatment-related neurological deficits were not significantly different (17% in MS patients versus 5% in RS patients; P ϭ 0.16).
Ruptured versus Unruptured AVMs.
No difference was observed between previously ruptured and unruptured AVMs with regard to hemorrhage recurrence, obliteration rate, and mortality and morbidity rates ( Table 6 ).
DISCUSSION
Some researchers have attempted to compare MS and RS using either a mathematical model (6) or a clinical comparison between a MS series and published RS results from the treatment of small AVMs (44, 51) . However, biases have been so high in these series that conclusions cannot be applied to actual practice. This is why the idea of randomization comes up from time to time; still, everyone is aware that it is nearly impossible. Moreover, evidence-based medicine and systematic literature reviews show little information regarding the clinical course and management of AVMs (2, 3) . Thus the problem was to compare the outcomes of two AVMs with nidi as similar as possible that were treated with MS or RS.
Statistical analysis of paired series is a well-known method that allows us to decrease confusion bias between the studied variables. This bias often occurs in compared-series studies. However, this method is difficult to invoke, because of the large number of patient records that must be reviewed before candidates may be chosen. In our series, we started with 705 patients who had AVM treated by RS and 150 patients who were treated by MS to finish with 39 patients in each group. Of course, our series could not be paired on all the possible variables; thus, differences will be observed (for example, on GCS at admission).
Statistical analysis of paired series can compare two small sets of quantitative data when the data in each sample set are related in a special way. We used the paired Student's t test, which is a parametric test and an alternative to the t test when samples are paired, to reduce incidental variation. t test compares samples that are subjected to different conditions, provided the samples in each pair are identical otherwise. The Wilcoxon signed-rank test could also be used instead of the paired Student's t test to avoid the normal distribution assumption, but with 39 patients in both groups, this was not mandatory. The limits of this study mainly involve the target population of patients with AVM to which the study is applicable. This study cannot compare MS and RS for all AVMs; rather, it is valid only for AVMs that could be suitably treated with either MS or RS. This means that the results of this study are valuable primarily when treating patients with small-sized AVMs. This study was performed to assist surgeons in identifying the best treatment choice when the decision is not straightforward. Other limits are those related to a retrospective study and include lost follow-up information. We elected to include complete records of patients in our study to compare all of the parameters; still, the study may underestimate the number of patients with poor outcome because there is no way to know how many of these individuals are among those who did not return for follow-up examinations. However, this underestimation is consistent within the study as it occurred in both groups of our series.
Comparison of Microsurgery and Radiosurgery
To compare these two techniques, it is necessary to first evaluate their safety and efficacy. We then must evaluate the influence of characteristics associated with the AVM, the patient, and the therapists for both of the techniques within published series to perform a comparison with our present series.
Safety of Microsurgery versus Radiosurgery
No efficient treatment for AVMs is risk-free. The principle is to propose to the patient a treatment that is judged to pose less risk than the AVM itself. Spontaneous AVM obliteration is rare (approximately 1.3% of all AVMs [42] ) and seems negligible. Thus, treatment is mandatory to prevent hemorrhage. Because the purpose of this study was to compare MS with RS, we will not discuss the risks of embolization.
Mortality
In our series, there was one death in the MS series versus zero deaths in the RS series. The one death was related to treatment complications of a Spetzler-Martin Grade III AVM and occurred 3 months after the patient underwent MS. For patients with Spetzler-Martin Grades I and II AVMs, we observed no mortality in our series. Because the difference (3% versus 0%) was not significant, the result emphasizes that MS includes a risk of death that is directly related to the treatment. Thus, mortality is a risk that is greater in MS than RS treatment, and this must be shared with the patient. Additionally, the risk period occurs within a short-term follow up after MS, whereas it has a more delayed time profile after RS. Conversely, the risk of death after RS is not related to the procedure; instead, it is related to the accepted risk of AVM hemorrhage until obliteration occurs. Although three patients experienced hemorrhage in the RS series, no mortality was observed.
In published series, mortality associated with AVM is mainly a result of hemorrhage (4) . Because the overall prospective actuarial rate of hemorrhage was evaluated to 4% per year per patient (41) and the overall mortality and morbidity by hemorrhage was determined to be 25% per hemorrhage, the rate of mortality and morbidity was 1% per year per patient. This rate was confirmed by Al-Shahi and Warlow (2), who performed a recent exhaustive, critical review of the literature. The first bleed was fatal in 4.6% of patients (4) . After the first hemorrhage, minor or no handicap was observed in approximately 75% of patients (4) . These data must be compared with the comparable risks of MS and RS.
In 2001, Castel and Kantor (5) performed an exhaustive review and analysis of AVM surgery literature from the last 10 years. The mean mortality rate associated with MS to treat AVM was 3.3%, and ranged from 0% to 15% (5). These rates were based on all AVMs regardless of size, location, or angioarchitecture. If we consider AVMs smaller than 3 cm (which could be suitable for RS), three series reported zero mortality regardless of location (43, 47, 51) . However, for Spetzler-Martin Grades I to III, there was low mortality (0% to 2%) with relatively low morbidity (1.9% to 12.6%). Although these rates seem to be low, no one can assert that a craniotomy even for a small AVM is risk-free.
Morbidity and Quality of Life
To compare both treatments, one must take into account a patient's pretreatment status to evaluate his or her final status. In the present series, although the GCS before treatment was slightly higher in RS patients (15 versus 13.46), the rate of pretreatment neurological deficits was not statistically different in the two groups. However, in RS patients, the GCS was higher 48 hours after treatment (15 versus 12.89), and the GOS was higher at discharge (4.89 versus 4.20) and 12 to 24 months after treatment (4.89 versus 4.38). Mean MRS was also significantly better after RS than after MS and improved during the time interval between discharge and the 12-to 24-month follow-up examination. Improvement scores were higher in the MS series (2.07 to 1.41) than in the RS group (1.10 to 0.95). Another important point is the higher rate of deficits related to treatment in the MS series (17% versus 5%), although it did not reach the signficance level. Even in patients with Spetzler-Martin Grades I and II AVMs, we observed significant morbidity. Thus, in our series, patient morbidity was higher after MS than after RS treatment. The morbidity rate was closely linked to the Spetzler-Martin grade, but was always higher in the MS series than in the RS series, regardless of grade. Morbidity related to MS of AVMs is often difficult to evaluate in published series, because patients exhibit mixed results of permanent neurological deficits, postoperative deficits, and long-term follow-up morbidity. The morbidity rate was never lacking, and the mean rate was 8.6% (range, 1.5% to 18.7%). For patients with AVMs smaller than 3 cm, there was a low rate of morbidity (1.5% to 9.7%). Morbidity is related to AVM size, and, more precisely, to the Spetzler-Martin grade. Moreover, patient morbidity was null for treatment of AVMs of Spetzler-Martin Grades I to III in the Hamilton and Spetzler series (16) . Most of the time, patient morbidity rates are less than 5% (1.9% to 12.6%) in other series (9, 11, 18, 19, 33, 34, 43, 44, 46) . In our series, one may argue that the deficit rate was high in patients with Spetzler-Martin Grades I and II AVMs, but these individuals seemed to be coherent with the recent study of Lawton et al. (25) . Parenchymal changes must also be considered, but the main parameter is the occurrence of a new neurological deficit that is created by the treatment.
Patient morbidity related to RS is a result of the AVM history until obliteration and to radioinduced parenchymal changes. In the RS series, three patients experienced hemorrhage after RS, but none of them had new neurological deficits. However, morbidity is reported to occur with AVM hemorrhage. In the series of Ondra et al. (41) , AVM hemorrhage led to a 2.7% per year actuarial rate of combined mortality and major morbidity, and a 1% per year rate of mortality. Thus the major morbidity rate was 1.7% per year, which yields an actuarial rate of hemorrhage of 4% per year. In the series by Hartmann et al. (17) , after AVM hemorrhage, 47% of patients had no neurological deficit, an additional 37% were independent in their daily activities (MRS of 1), 13% were moderately disabled (MRS of 2 or 3), and 3% were severely disabled (MRS Ն 4). Parenchymal hemorrhages were most likely to result in neurological deficits (52% for Hartmann et al. [17] , and 60.7% for our series of 705 RS patients [40] ).
In our series of 705 patients who were treated using RS (40), 5.37% of patients had neurological deficits related to the RS, but these deficits remained permanent in only 1.46% of patients. In the present series, there was a 5% rate of radioinduced deficit. Deficits occurring during the latency period until AVM obliteration must be added to this rate, because of the accepted risk of hemorrhage until obliteration.
Efficacy of Microsurgery versus Radiosurgery
The assessment of efficacy is based on two parameters, namely, the hemorrhage risk after AVM treatment and the angiographic evaluation.
Hemorrhage Risk
In the present series, hemorrhage occurred in 10% of patients after RS with an actuarial rate of 2.70% per year. No hemorrhage occurred in patients treated with RS. Thus, MS appears to be superior to RS with respect to the rate of recurrent bleeding after RS, which is because of the latency period that occurs until obliteration of the AVM (P ϭ 0.04) and the high oblitera-tion rate associated with MS. In the series of Ondra et al. (41) , the actuarial risk of AVM hemorrhage was evaluated to be 4% per year per patient. The risk of recurrent hemorrhage is probably greater than the 4% baseline risk, and may be high as 18% in the first year (31) . However, individual hemorrhage risk for a given AVM could be measured with more accuracy. Many publications show that the hemorrhage risk of an AVM seems to be related to clinical symptoms, size, location, hemodynamics, and angioarchitecture (37) .
After MS to treat AVM, the risk of hemorrhage is related to the rate of complete AVM excision, which is very high at 97% (91% to 100% between series) (5) . But this rate is related to the initial goal of surgery, which is to perform complete AVM excision. This confers a very low rate of hemorrhage to the MS procedure (the lowest rate of all available AVM treatments).
Many authors have studied the AVM hemorrhage risk that is associated with RS. Although some series seem to show that global risk decreases (22, 23, 30) or increases (8) after RS, most studies show that the risk remains stable (27, 35, 45) . This risk is related to the AVM population that is treated using RS, and individual risk depends on AVM hemorrhage risk factors and characteristics that predict a poor level of obliteration (35) .
Angiographic Evaluation and Obliteration Rate
Anatomic evaluation after treatment was based on conventional angiography for all patients of our series. At present, although new, less-invasive imaging sequences are increasingly available, after treatment of an AVM, the higher sensitivity and specificity of conventional angiography makes it the mandatory choice for evaluating the quality of AVM excision or obliteration. In the present series, the obliteration rate associated with MS was 92% and with RS was 81% (P ϭ 0.10), whereas the mean percentage of obliteration (mean obliteration rate) was the same in patients treated with MS and RS. The hemorrhage rate was 0% in MS patients versus 10% in RS patients (P ϭ 0.04). In both the published series and the present series, there was a strong trend for higher efficiency of MS versus RS for the obliteration rate and the rate of hemorrhage recurrence after treatment, even when our obliteration rate was lower for MS patients than in published series.
In the MS series, angiography confirmed complete excision of the AVM in 97% (1050 out of 1076 patients; range, 91% to 100%) in 11 series (5). For patients with AVMs smaller than 3 cm, rates of cure ranged from 98% (47) to 100% (51) . This rate of cure is the highest associated with any AVM treatment.
In the RS series, the rate of cure was difficult to assess because of great differences between series with respect to the patient populations, AVMs, types of RS devices, patient follow up, and the definition and calculation of the obliteration rate. The cohort of patients with AVMs treated using RS is variable with respect to AVM onset, patient age, and AVM size, volume, and location. Although some series include mostly low-volume AVMs (7, 26, 59 ), others included a higher proportion of high-volume AVMs (15, 49) with different obliteration rates. Moreover, results are presented as a function of size or volume classes, which vary between series. Sometimes, size or volume are not even mentioned within a report (10, 11) . Concerning symptoms and age at AVM onset, differences were noticeable and could be an index of the heterogeneity of AVMs treated. Some series display results stratified by size and volume; the smaller the AVM, the higher obliteration rate (8, 13, 40, 55) . But "small" and "large" do not necessarily have the same definition between series.
Patient Factors
Patient life expectancy is an important parameter of decision making when MS and RS are both suitable treatment options. These factors can be classified as neurological condition as it relates to the AVM and other comorbidities. A bad clinical grade is often associated with a poor outcome apart from a compressive hematoma if it can be removed. In the present series, pretherapeutic GCS values were higher for patients treated using RS (15 in RS versus 13.58 in MS; P ϭ 0.0049) and may influence the outcome. GOS and MRS measured postoperatively, at discharge, and during follow-up examination were always higher in patients treated with RS than with MS.
Advancing age is associated with a worse outcome in AVM surgery (24) and can influence the therapeutic strategy toward the RS option. RS requires only local anesthesia, and comorbidities associated with age can influence the risk associated with general anesthesia. Moreover, because the risk of hemorrhage seems to be an actuarial risk, it is lower in older than in younger patients and may also influence the strategy toward RS because of the balance of risks of both AVM and treatment. This led us to include age as a parameter for pairing the two series, to compare patients with risks as closely as possible.
Occupation and hobbies, family responsibilities, psychological makeup, and psychological reaction to the knowledge of having an AVM are also important parameters to consider in decision making (20) . Quality of life for patients with an untreated AVM was studied in recent series (50, 57) . These authors showed that patients with untreated AVM experience reduced quality of life, mainly within the psychosocial domain. However, scores for anxiety and depression were essentially the same as those in the reference population (57) . This is an important argument for involving the patient in decision making regarding his or her own management.
Arteriovenous Malformation Factors
Value of the Spetzler-Martin Grade. Spetzler and Martin's grading system was published in 1986 to assist clinicians with predicting patient mortality and morbidity after MS of an AVM (53) . This system became a means of comparing all published AVM series, because of its simplicity, its reproducibility, and its correlation to the outcome of patients operated on. Nevertheless, it has limits. First, absolute values of rates for mortality and morbidity that are associated with each grade could not be transposed to any neurosurgeon, especially if he or she is not trained for vascular surgery. Second, if there is only one type of Grade I AVM that is smaller than 3 cm, is not in eloquent area, and has no deep drainage, and only one type of Grade V AVM that is larger than 6 cm, is in eloquent area, and has deep drainage, then there is great heterogeneity for Grade II (three different types), Grade III (four different types), and Grade IV (three different types). Although this heterogeneity has less influence for MS, it is of major importance for RS. A Grade III AVM that is smaller than 3 cm, is in eloquent location, and has deep drainage is a priori a good candidate for RS, whereas it would be absurd to treat by RS alone a Grade III AVM that is larger than 6 cm, is in an ineloquent location, and has no deep drainage. Moreover, in a recent study, Du et al. (12) showed that despite precise quantitative definitions, the Spetzler-Martin grading scale is subject to interobserver variability, especially when observers differ in their subspecialties. Even angiography evaluation may depend on the observer (1). This study was performed with a neuroradiologist and a neurosurgeon, and differences were observed primarily for eloquence areas and size. Thus the Spetzler-Martin scale is not relevant for RS, but it can be used to compare series and to evaluate risks of MS for a given AVM in the therapeutic discussion. We use it in our series to pair patients and AVMs, and to stratify results as functions of each grade to compare them to published series.
In the present series, Spetzler-Martin grade was one of the parameters used to make paired series. Posttherapeutic status was correlated with grade; the higher the grade, the lower the neurological condition. This is also true for the follow-up examinations. The rate of obliteration was also approximately correlated with the grade regardless of treatment, but different types of different grades could not be statistically studied.
Arteriovenous Malformation Size. AVM size is one of the three parameters of the Spetzler-Martin scale. This is also one of the parameters used for pairing series. But if analyzed alone, it is of major influence on operative difficulties and, thus, risks, mortality, and morbidity as previously described. For example, complete excision was achieved in 98% of patients for Schaller and Schramm (47) and in 100% for Sisti (51, 52) . Moreover, size is a main parameter for the choice of treatment since RS can easily treat AVM less than 20 to 30 mm because of the ability to give a curative dose on the nidus with an acceptable risk of radioinduced parenchymal changes. As the size (or volume) of the AVM increases, the ratio of cure/radioinduced lesions reverses.
Angioarchitecture. As previously described, angioarchitecture is probably the main parameter associated with the risk of AVM hemorrhage and is clearly related to AVM location and clinical symptoms (14, 28, 29, 32, 38, 39, 56, 58) . We could not stratify AVMs of the present series on the basis of angioarchitectural factors because of the small number of patients in each series. However, if an AVM includes high risk factors for hemorrhage, such as intranidal or paranidal aneurysms, it seems illogical to choose a treatment that has associated delayed effects. MS may be preferred in such cases.
Location. The location of the AVM is also an important factor to consider with regard to both Spetzler-Martin grade and angioarchitecture, as previously described. Cortical AVMs have drainage in cortical veins, which have lower risk of hemorrhage than deep AVMs with deep drainage (36) . However, lessdangerous AVMs (superficial AVMs, which have the lowest risk of hemorrhage and a low Spetzler-Martin grade) are often the easier AVMs to operate on.
Team Experience
Neurosurgeon Experience and Ethical Considerations. RS is performed by a multidisciplinary team; however, the microsurgical procedures are highly dependent on the neurosurgeon. The situation is different for a RS team, even if the number of patients treated by the team plays a role in the results. Mortality and morbidity rates given in an expert's series cannot always be transposed to any team or any neurosurgeon. Thus the neurosurgeon must honestly evaluate his experience and capabilities to make the right choice and to perform operative procedures on a patient with an AVM. This is true for all patients with AVMs, especially when the AVM is unruptured. This has been stressed in an excellent article by Heroes (20) . The neurosurgeon has a major role and responsibility to decide what is best for the patient and the team. If the neurosurgeon is convinced that one treatment is superior over another, he or she must present the alternatives with their risks and enlighten the patient, especially regarding the balance between the risks of the AVM and the risks of the treatment. The final decision is still the patient's, but it is influenced by the physician's proposals. When considering surgery, a neurosurgeon does not have to hesitate to refer a patient to a colleague for a second opinion, especially if the patient prefers surgery when the team is advising other treatment modalities.
In the present series, the overall benefits and risks of MS seem to be balanced with the benefits and risks of RS, with the higher risks of MS being the price to pay for a better cure. In such cases where the risks, the benefits, and thus the decision of choice are on the line, the patient's opinion must be emphasized.
Unruptured versus Ruptured Arteriovenous Malformations. In our series, the percentage of cure was not statistically different in ruptured versus unruptured AVMs regardless of treatment (88.5% versus 100% for MS patients and 80.8% versus 83.8% for RS patients). Moreover, deficits related to treatment were comparable in MS and RS, but with a tendency to be higher in MS patients if the AVM was unruptured and lower in RS patients if the AVM was ruptured.
Two situations may require urgent treatment for AVM. In the case of a ruptured AVM with a compressive hematoma, urgent surgery is often necessary. If angiography shows an intranidal or paranidal aneurysm, often this aneurysm will be cured either by embolization or by surgery, and the treatment will also be performed shortly after hemorrhage because of the high hemorrhage risk associated with this kind of aneurysm. But unlike the situation that occurs when dysplastic aneurysms rupture, AVMs have a relatively low risk of short-term hemorrhage recurrence. Except these two situations, emergency AVM treatment is not the rule.
Apart from these cases, one may ask whether the occurrence of a previous hemorrhage should influence the therapeutic strategy. Most certainly, at first look, a previous hemorrhage may lead to the selection of a treatment that is able to avoid additional hemorrhage as quickly as possible. Lawton et al. (25) showed recently that surgery for unruptured AVM may lead to higher morbidity than classically admitted and published in previous series, and argued that clinicians should consider with more prudence surgery for patients who did not undergo previous hemorrhage of their AVM.
CONCLUSION
In practicing evidence-based medicine, we strive to increase the level of evidence for medical management; however, little information is available to direct the clinical course and management of AVM, especially to compare different AVM treatments. To our knowledge, this type of study, comparing the results and risks of MS and RS in two paired series of 39 cases with similar pretreatment patient and AVM characteristics, has never been reported.
Considering the results of our study on paired series, MS seems to provide higher efficacy with higher risks than RS but without a statistically significant difference in hemorrhage risk. These data are not sufficient to claim the superiority of one treatment over another. The most important element of data is the hierarchy of priorities given by the patient and the therapist. If the goal is the quickest cure, there is a "price to pay" with higher risks. However, the quickest cure may be required and recommended if the patient's AVM has angioarchitectural factors of hemorrhage.
For a given team that is experienced with AVM management, it is important to adapt the treatment to the AVM (including its angioarchitecture and history) and to the patient, who must be involved in the therapeutic decision. The hierarchy of exigencies must be analyzed for each patient and for each AVM.
Because there were good correlations between our series and the literature data, we think that this report is a valuable contribution to physicians who discuss treatment recommendations. It is especially useful in those cases where the AVM may be treated suitably using either method, as these most often give a clinician pause.
The evolution shows that informed patients more and more frequently choose noninvasive RS. Accordingly, one can anticipate that the number of these situations of choice between MS and RS for cure of an AVM will decrease. However, we think that the results of the present study may help the physician and the patient to reach an informed consent, regardless of the final therapeutic choice.
rate than radiosurgery. This study further underscores the important point that treatment for a particular AVM must be individualized based on the patients' presenting symptoms, anatomic characteristics of the AVM, patient age, etc. Furthermore, larger centers with neurosurgeons who treat AVMs both with microsurgery and radiosurgery may be better able to provide the risks and benefits of each option compared with institutions that do not have both treatment modalities. As with other studies in which a large number of patients are reduced to smaller groups in order to make head-to-head comparisons, there is a risk of potential selection bias. However, the two groups that the authors have presented seem to be quite comparable for the most part.
Steven D. Chang Stanford, California
B
etween 1984 and 1998, the authors performed a retrospective casecontrol trial of 39 matched patients in two treatment arms, microsurgery and radiosurgery. Retrospectively, all 78 patients were deemed suitable for either procedure. Patients were collected from two institutions, with one institution providing radiosurgical treatment and the other providing microsurgical treatment. Patients were well matched for a number of factors, including clinical presentation, hemorrhage, Spetzler-Martin grade, AVM location, age, and sex. Patients were not matched for associated aneurysms. The median follow-up period was relatively short (12 months for the entire group). Follow-up angiography was obtained in all patients to determine obliteration rates.
The authors concluded that radiosurgery was associated with a lower treatment-related morbidity rate but was associated with a higher rate of AVM rupture (2.6% per year compared with 0% for microsurgery) and a lower rate of AVM obliteration at the time of the last follow-up examination after treatment. None of the postradiosurgery AVM ruptures caused significant morbidity.
These findings are not surprising. One must recall that the study is biased against microsurgery. The longer follow-up in the radiosurgery group (current median follow-up in the radiosurgery group, 25 months) would only increase the rate of morbidity from potential hemorrhages. This is a good study and the data provided will facilitate decision making for the individual patient.
Iman Feiz-Erfan Robert F. Spetzler Phoenix, Arizona I t is very difficult to compare microsurgical and radiosurgical outcomes for any disorder in a meaningful fashion. The findings of this study confirm what most clinicians believe and what previous studies have noted regarding AVM treatment. However, this study makes one question the basis of one's treatment recommendations for AVM patients. Neurosurgeons have long contended that the most important management goal for patients with cerebral AVMs is to reduce the risk of hemorrhage or recurrent hemorrhage and its associated morbidity. Primarily, this is accomplished by either surgical removal or radiosurgery. Surgical resection provides immediate protection from bleeding in the majority of cases, whereas radiosurgery does so with less certainty and over a period of years for most patients. Conversely, neurologists more frequently discuss that the risk and morbidity of AVM bleeding may be less than previously believed, and observation of AVMs, especially for patients with unruptured AVMs, may be the preferred management strategy (1) . It is argued that maintenance of quality of life rather than AVM elimination should be the primary metric used to assess and compare different AVM treatments. Although it is likely that the Randomized Trial of Unruptured Brain AVMs Study will provide additional information on this discussion, it will also be subject to a number of methodological issues such as selection bias and shortterm follow-up that may subtract from its findings. We reviewed outcomes after AVM radiosurgery for 243 patients undergoing radiosurgery between 1990 and 2001 using the Modified Rankin Scale (MRS) as the primary statistical endpoint (2) . At a mean follow-up period of 65 months, 41 patients (17%) sustained a decline in MRS score (median, 2) after AVM radiosurgery. We noted a decline in MRS score in 4% of the patients 1 year after radiosurgery, in 8% of the patients at 3 years after radiosurgery, and in 15% of the patients at 7 years after radiosurgery. In addition, the radiosurgery-based AVM score (3) correlated with a decline in MRS after AVM radiosurgery in multivariate testing; no patients with an AVM score of one or less experienced a change in neurological function after radiosurgery. Therefore, a clinical equipoise is often reached when discussing the results of surgical resection and radiosurgery for patients with small, unruptured AVMs.
Bruce E. Pollock
Rochester, Minnesota
